79 related articles for article (PubMed ID: 3739859)
21. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
22. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
23. [Possibilities for the use of exfoliative urine cytology in invasive and noninvasive bladder cancer].
Stadie G; Ebert W; Müller H
Z Urol Nephrol; 1985 Jun; 78(6):331-7. PubMed ID: 4036385
[TBL] [Abstract][Full Text] [Related]
24. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
25. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
26. [Value of exfoliative cytology of the urinary bladder in occult bladder cancer and in the control of treated cancers].
Schmitz A; Meyer U; Kierfeld G; Küchemann K
Urologe A; 1984 Sep; 23(5):278-80. PubMed ID: 6542269
[TBL] [Abstract][Full Text] [Related]
27. [Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG].
Pieras Ayala E; Palou J; Rodríguez-Villamil L; Millán Rodríguez F; Salvador Bayarri J; Vicente Rodríguez J
Arch Esp Urol; 2001 Apr; 54(3):211-7. PubMed ID: 11432035
[TBL] [Abstract][Full Text] [Related]
28. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
29. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
31. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
32. Natural history of positive urinary cytology after radical cystectomy.
Raj GV; Bochner BH; Serio AM; Vickers A; Donat SM; Herr H; Lin O; Dalbagni G
J Urol; 2006 Nov; 176(5):2000-5; discussion 2005. PubMed ID: 17070236
[TBL] [Abstract][Full Text] [Related]
33. Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?
Karl A; Tritschler S; Stanislaus P; Gratzke C; Tilki D; Strittmatter F; Knüchel R; Stief CG; Zaak D
BJU Int; 2009 Feb; 103(4):484-7. PubMed ID: 18793301
[TBL] [Abstract][Full Text] [Related]
34. [Studies on multiple mucosal biopsy in patients with bladder cancer. 2. Evaluation on the relationship between the results of multiple mucosal biopsy and recurrence, and the clinical course of cases with carcinoma in situ and micro-invasion of carcinoma in situ].
Igawa M
Hinyokika Kiyo; 1986 Nov; 32(11):1633-47. PubMed ID: 3825813
[TBL] [Abstract][Full Text] [Related]
35. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
Asali MG; Kaneti J; Manor E
Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer.
Wiener HG; Vooijs GP; van't Hof-Grootenboer B
Acta Cytol; 1993; 37(2):163-9. PubMed ID: 8465635
[TBL] [Abstract][Full Text] [Related]
37. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
38. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
[TBL] [Abstract][Full Text] [Related]
39. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.
Mian C; Lodde M; Comploj E; Palermo S; Mian M; Maier K; Pycha A
Anticancer Res; 2005; 25(5):3641-4. PubMed ID: 16101194
[TBL] [Abstract][Full Text] [Related]
40. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal.
Kipp BR; Halling KC; Campion MB; Wendel AJ; Karnes RJ; Zhang J; Sebo TJ
J Urol; 2008 Apr; 179(4):1296-301; discussion 1301. PubMed ID: 18289582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
